Human Papillomavirus Screening in North Indian Women

  • Pandey, Saumya (Krishna Medical Center, Chhatrapati Shahuji Maharaj Medical University) ;
  • Mishra, Malvika (Krishna Medical Center, Chhatrapati Shahuji Maharaj Medical University) ;
  • Chandrawati, Chandrawati (Krishna Medical Center, Chhatrapati Shahuji Maharaj Medical University)
  • Published : 2012.06.30


Objectives: Human papillomavirus (HPV) is the major etiological agent of cervical cancer, a leading cause of morbidity and mortality in women worldwide. Screening strategies for reducing the burden of HPV-mediated carcinogenesis are emerging as an effective means for cervical cancer control and prevention in developing countries. Our study, therefore, aimed to identify HPV infection status in North Indian women during random population screening. Methodology: Cervical/vaginal exfoliated cells and/or Pap smear specimens were collected from 890 women of North Indian ethnicity residing in Lucknow and adjoining areas, during random population screening from June 2009-March 2012. HPV viral loads in clinical specimens were determined by the Hybrid Capture (hc)-2 HPV DNA assay, and subsequently, positive/negative/borderline HPV status was calculated. Results: The HPV incidence in the present study was 11.7%. 751 out of a total of 890 women (84.4%) participating in our HPV screening program were HPV negative (HPV -), 104 (11.7%) tested positive (HPV +) while 35 (3.9%) showed borderline (HPV $^*$) infection status. Furthermore, in the HPV + subjects (N=104), 18 (17.3%) showed strong positivity. We observed that HPV positivity tends to increase with age in North Indian women; the higher the viral load with increasing age, higher is the susceptibility to HPV-mediated cervical cancer. Conclusions: HPV viral load/genotyping may help in identifying women at risk of developing cervical cancer. However, cost-effective HPV screening protocols with a wider population coverage are warranted so as to reduce the burden of cervical cancer in women worldwide in the vaccine-era.


  1. Bharadwaj M, Hussain S, Nasare V, Das BC (2009). HPV & HPV vaccination: Issues in developing countries. Indian J Med Res, 130, 327-33.
  2. Bosch FX, Lorincz A, Munoz N, et al (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.
  3. Bosch F (2003). Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica Mex, 45, 326-39.
  4. Bosch FX, Castellsague X, S de Sanjose (2008). HPV and cervical cancer: screening or vaccination? Br J Cancer, 98, 15-21.
  5. Bovicelli A, Bristow RE, Montz FJ (2000). HPV testing: where are we now? Anticancer Res, 20, 4673-80.
  6. Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the european and north American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101.
  7. Dabash R, Vajpayee J, Jacob M, et al (2005). A strategic assessment of cervical cancer prevention and treatment services in 3 districts of Uttar Pradesh, India. Reprod Health, 2, 11.
  8. Das BC, Hussain S, Nasare V, Bharadwaj M (2008). Prospects and prejudices of human papillomavirus vaccines in India. Vaccine, 26, 2669-79.
  9. Denny L, Quinn M, Sankaranarayanan R (2006). Chapter 8: Screening for cervical cancer in developing countries. Vaccine, 24, 71-7.
  10. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002 (2004). Cancer incidence, mortality and prevalence worldwide, version 2.0. IARC Cancer Base No. 5 Lyon, France: IARC Press.
  11. Ganguly N, Parihar SP (2009). Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci, 34, 113-23.
  12. Harper DM, Franco EL, Wheeler C, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 364, 1757-65.
  13. Harper DM, Franco EL, Wheeler C, et al (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 367, 1247-55.
  14. Hildesheim A, Schiffman MH, Gravitt PE, et al (1994). Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis, 169, 235-40.
  15. International Agency for Research on Cancer (2005). IARC Handbooks of Cancer Prevention. Cervix Cancer Screening. Lyon: IARC Press.
  16. Jo H, Kim JW (1998). Implications of HPV infection in uterine cervical cancer. Sex Transm Inf, 74, 101-9.
  17. Li TT, Zhao LN, Liu ZG, Han Y, Fan DM (2005). Regulation of apoptosis by the papillomavirus E6 oncogene. World J Gastroenterol, 11, 931-7.
  18. Longworth MS, Laimins LA (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol Biol Rev, 68, 362-72.
  19. Mayrand MH, Duarte-Franco E, Rodrigues I, et al (2007). Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med, 357, 1579-88.
  20. Miller AB (1992). Cervical cancer screening programmes: managerial guidelines. Geneva: World Health Organization.
  21. Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T (2004). The role of human papillomavirus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci, 50, 9-19.
  22. Ronco G, Segnan N, Giorgi-Rossi P, et al (2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, 98, 765-74.
  23. Sankaranarayanan R, Okkuru Esmy P, Rajkumar R, et al (2007). Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet, 370, 398-406.
  24. Solomon D, Schiffman M, Tarone R (2001). Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst, 93, 293-99.
  25. Stamenkovic I (2000). Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol, 10, 415-33.
  26. Stoler MH (2001). HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J Histochem Cytochem, 49, 1197-8.
  27. Villa LL, Costa RL, Pettac A, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8.
  28. Villa LL, Ault KA, Guiliano AR, et al (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24, 5571-83.
  29. Villa LL, Costa RLR, Petta CA, et al (2007). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus like particle vaccine through 5 years follow-up. Br J Cancer, 6, 1459-66.
  30. Villers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H (2004). Classification of papillomaviruses. Virology, 324, 17-27.
  31. Vizcaino AP, Moreno V, Bosch FX, et al (2000). International trends in incidence of cervical cancer: II. Squamous - cell carcinoma. Int J Cancer, 86, 429-35.<429::AID-IJC20>3.0.CO;2-D
  32. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  33. Zur Hausen H (1991). Viruses in human cancers. Science, 254, 1167-73.
  34. Zur Hausen H (2002). Papillomaviruses and cervical cancer. Nat Rev, 2, 342-50.

Cited by

  1. Autophagy in Cervical Cancer: An Emerging Therapeutic Target vol.13, pp.10, 2012,
  2. Genotype Distribution and Behavioral Risk Factor Analysis of Human Papillomavirus Infection in Uyghur Women vol.14, pp.10, 2013,
  3. Estimation of Cancer Cases Using Capture-Recapture Method in Northwest Iran vol.14, pp.5, 2013,
  4. Cancer and Infectious Causes vol.04, pp.03, 2014,
  5. Development and Clinical Evaluation of Dendritic Cell Vaccines for HPV Related Cervical Cancer - a Feasibility Study vol.15, pp.14, 2014,
  6. Population-based Cervical Cancer Screening Using High-risk HPV DNA Test and Liquid-based Cytology in Northern Thailand vol.15, pp.16, 2014,
  7. Type-specific Prevalence of Human Papillomavirus by Cervical Cytology among Women in Brasov, Romania vol.15, pp.16, 2014,
  8. Acceptability of Self-Sampling HPV Testing Among Thai Women for Cervical Cancer Screening vol.15, pp.17, 2014,
  9. Hybrid Capture 2 Assay Based Evaluation of High-Risk HPV Status in Healthy Women of North-East India vol.15, pp.2, 2014,
  10. Prevalence of Human Papillomavirus Types and Phylogenetic Analysis of HPV-16 L1 Variants from Southern India vol.16, pp.5, 2015,
  11. Investigation of Transition Types of HPV DNA Test Results over Time in Korean Women vol.16, pp.8, 2015,
  12. Update knowledge on cervical cancer incidence and prevalence in Asia vol.16, pp.9, 2015,
  13. Knowledge and Acceptability of Human Papillomavirus Vaccination and Cervical Cancer Screening among Women in Karnataka, India vol.30, pp.1, 2015,
  14. Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer vol.30, pp.6, 2016,
  15. Spousal migration and human papillomavirus infection among women in rural western Nepal vol.8, pp.4, 2016,
  16. Bayesian adjustment for over-estimation and under-estimation of gastric cancer incidence across Iranian provinces vol.9, pp.2, 2017,
  17. Reduced expression of autophagy markers correlates with high-risk human papillomavirus infection in human cervical squamous cell carcinoma vol.8, pp.4, 2014,